PMGC Holdings Inc.
ELAB · XNASCIK 1840563fmd_0W1F72XR298989JVJJXTMQBQ9DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Jun 30, 2026, 16 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | 1 | 2 | – | 1 |
| Cost of revenue | 0 | 2 | – | 0 |
| Gross profit | 0 | 1 | – | 0 |
| Realized investment gains (losses) | – | – | – | (0) |
| Operations and maintenance | – | – | – | 1 |
| Research and development | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 1 | 3 | – | – |
| Total operating expenses | 2 | 1 | 4 | 7 |
| Operating income | (2) | (0) | – | (7) |
| Interest expense | 0 | 0 | 1 | 0 |
| Interest and investment income | – | 0 | 0 | 0 |
| Other non-operating income (expense) | (2) | (4) | – | – |
| Income before taxes | – | – | (4) | (8) |
| Income tax expense | – | – | – | 0 |
| Net income from continuing operations | – | (2) | (4) | (8) |
| Net income | (2) | (4) | (6) | (8) |